---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-012479"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:08:53.100577+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma renews CEO Michael Breen for two-year term, effective April 29, 2025

## Summary
- CEO Michael Breen's employment renewed for two years from April 29, 2025, with automatic two-year renewals unless 90-day notice given.
- Breen continues as Executive Chairman and CEO; may perform duties from UK or elsewhere outside US.
- Amendment No. 3 signed August 26, 2025, retroactively effective April 29, 2025.
- No other changes to Breen's compensation or benefits under the existing employment agreement.

## SEC filing metadata
- accession: 0001493152-25-012479
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315225012479/0001493152-25-012479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315225012479/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-012479
- JSON: https://secwatch.observer/filing/0001493152-25-012479.json
- Plain text: https://secwatch.observer/filing/0001493152-25-012479.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.